Australia - inglés - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - fish oil - rich in omega-3 acids, quantity: 30 g/l; medium chain triglycerides, quantity: 60 g/l; olive oil, quantity: 50 g/l; soya oil, quantity: 60 g/l - injection, intravenous infusion - excipient ingredients: dl-alpha-tocopherol; egg lecithin; glycerol; sodium oleate; sodium hydroxide; water for injections - parenteral nutrition for adult patients and paediatric patients aged 2 years and above when oral or enteral nutrition is impossible, insufficient or contraindicated.

Estados Unidos - inglés - NLM (National Library of Medicine)

fresenius kabi usa, llc - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok), soybean oil (unii: 241atl177a) (soybean oil - unii:241atl177a), sodium acetate (unii: 4550k0sc9b) (sodium cation - unii:lyr4m0nh37, acetate ion - unii:569dqm74sc), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698), sodium glycerophosphate anhydrous (unii: yp1h63lj2k) (sodium cation - unii:lyr4m0nh37, phosphate ion - unii:nk08v8k8hr), magnesium sulfate heptahydrate (un - dextrose monohydrate 9.8 g in 100 ml - kabiven is indicated as a source of calories, protein, electrolytes and essential fatty acids for adult patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. kabiven may be used to prevent essential fatty acid deficiency or treat negative nitrogen balance in adult patients. limitations of use: kabiven is not recommended for use in pediatric patients under the age of 2 years, including preterm infants because the fixed content of the formulation does not meet the nutritional requirements of this age group [see warnings and precautions (5.1) and use in specific populations (8.4)] . the use of kabiven is contraindicated in: - neonates (28 days of age or younger) receiving concomitant treatment with ceftriaxone, even if separate infusion lines are used, due to the risk of fatal ceftriaxone calcium salt precipitation in the neonate's bloodstream [see limitations of use (1), warnings and precautions (5.5), use in specific populations (8.4)]. - pat

Australia - inglés - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - moxifloxacin hydrochloride, quantity: 1.75 mg/ml - injection, intravenous infusion - excipient ingredients: sodium sulfate; sulfuric acid; sodium acetate trihydrate; water for injections - moxifloxacin kabi intravenous solutions are indicated for treatment of adults who require initial iv therapy for the treatment of infections in the conditions:,- community acquired pneumonia (caused by susceptible organisms),- acute exacerbations of chronic bronchitis when caused by organisms bacteriologically proven to be resistant to other classes of antibiotics or when there is intolerance to other antibiotics,- moxifloxacin kabi intravenous solutions are indicated for treatment of adults with severe and complicated skin and skin structure infections who require initial parenteral therapy, and who have intolerance to alternative agents, (especially penicillin allergy), and when caused by organisms known to be susceptible to moxifloxacin.,appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with moxifloxacin kabi may be initiated, in some conditions, before results of these tests are known. once results become available, therapy should be continued with the most appropriate antibiotic therapy.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - moxifloxacin hydrochloride, quantity: 1.75 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections; sodium acetate trihydrate; sodium sulfate; sulfuric acid - moxifloxacin kabi intravenous solutions are indicated for treatment of adults who require initial iv therapy for the treatment of infections in the conditions:,- community acquired pneumonia (caused by susceptible organisms),- acute exacerbations of chronic bronchitis when caused by organisms bacteriologically proven to be resistant to other classes of antibiotics or when there is intolerance to other antibiotics,- moxifloxacin kabi intravenous solutions are indicated for treatment of adults with severe and complicated skin and skin structure infections who require initial parenteral therapy, and who have intolerance to alternative agents, (especially penicillin allergy), and when caused by organisms known to be susceptible to moxifloxacin.,appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with moxifloxacin kabi may be initiated, in some conditions, before results of these tests are known. once results become available, therapy should be continued with the most appropriate antibiotic therapy.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - metronidazole, quantity: 500 mg - injection, solution - excipient ingredients: citric acid monohydrate; water for injections; sodium chloride; dibasic sodium phosphate dodecahydrate - metronidazole intravenous infusion is indicated:,(a) for treatment of anaerobic infections in patients for whom oral administration is not possible.,(b) where immediate anti-anaerobic chemotherapy is required.,(c) where prophylactic cover is required at lower abdominal surgical sites presumed contaminated or potentially contaminated by anaerobic micro-organisms. procedures of this type include appendectomy, colonic surgery, vaginal hysterectomy, abdominal surgery in the presence of anaerobes in the peritoneal cavity and surgery performed in the presence of anaerobic septicaemia.,note: metronidazole is inactive against aerobic or facultative anaerobic bacteria.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - meropenem trihydrate, quantity: 1140 mg (equivalent: meropenem, qty 1000 mg) - injection, powder for - excipient ingredients: sodium carbonate - indications,meropenem kabi is indicated for treatment of the following infections, in adults and children (aged 3 months and over), when the causative organisms are known or suspected to be resistant to commonly used antibiotics:,? community acquired lower respiratory tract infection ,? hospital acquired lower respiratory tract infection,? complicated urinary tract infection,? febrile neutropaenia,? intra-abdominal and gynaecological (poly microbial) infections,? complicated skin and skin structure infections,? meningitis,? septicaemia

Australia - inglés - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - meropenem trihydrate, quantity: 570 mg (equivalent: meropenem, qty 500 mg) - injection, powder for - excipient ingredients: sodium carbonate - indications,meropenem kabi is indicated for treatment of the following infections, in adults and children (aged 3 months and over), when the causative organisms are known or suspected to be resistant to commonly used antibiotics:,? community acquired lower respiratory tract infection ,? hospital acquired lower respiratory tract infection,? complicated urinary tract infection,? febrile neutropaenia,? intra-abdominal and gynaecological (poly microbial) infections,? complicated skin and skin structure infections,? meningitis,? septicaemia

Malta - inglés - Malta Medicines Authority

fresenius kabi oncology plc lion court, farnham road, bordon, hampshire, gu35 0nf, united kingdom - capecitabine - film-coated tablet - capecitabine 150 mg - antineoplastic agents

Malta - inglés - Malta Medicines Authority

fresenius kabi oncology plc lion court, farnham road, bordon, hampshire, gu35 0nf, united kingdom - capecitabine - film-coated tablet - capecitabine 500 mg - antineoplastic agents

Australia - inglés - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - flumazenil, quantity: 0.1 mg/ml - injection, solution - excipient ingredients: acetic acid; sodium hydroxide; disodium edetate; sodium chloride; water for injections - flumazenil kabi is indicated for use in hospitalised patients for the reversal of acute benzodiazepine effects (overdose or therapeutic). hospitalised patients are patients admitted to hospital, inpatient care and under continued professional observation while under the influence of flumazenil. not to be used in outpatients or short stay patients. not to be used as a diagnostic.